Earnings call: Takeda maintains guidance despite profit decline
==========

Takeda Pharmaceutical Company reported its third-quarter earnings for fiscal year 2023, maintaining its full-year management guidance despite a decline in core operating profit. The company's revenue increased slightly, driven by growth and launch products, which now account for 43% of total revenue. Takeda faced a significant challenge from the entry of generic competitors to its Vyvanse drug in the U.S. market. Takeda remains committed to its strategy for sustained growth, emphasizing the expansion of its product portfolio, investment in research and development, and the use of data and digital technologies.

#TakedaPharmaceuticalCompany #EarningsCall #ProfitDecline

https://www.investing.com/news/stock-market-news/earnings-call-takeda-maintains-guidance-despite-profit-decline-93CH-3291832